Cargando…

A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer

Hyperthermic intravesical chemotherapy (HIVEC)—whereby the bladder is heated to ± 43 °C during a chemotherapy instillation—can improve outcomes of non-muscle invasive bladder cancer (NMIBC) treatments. Experiments in animal models are required to explore new hyperthermia based treatments. Existing H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Hattum, J. W., Scutigliani, E. M., Helderman, R. F. C. P. A., Zweije, R., Rodermond, H. M., Oei, A. L., Crezee, J., Oddens, J. R., De Reijke, T. M., Krawczyk, P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054747/ https://www.ncbi.nlm.nih.gov/pubmed/35488115 http://dx.doi.org/10.1038/s41598-022-11016-y

Ejemplares similares

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
por: Guerrero-Ramos, Félix, et al.
Publicado: (2022)

A Four-Inflow Construction to Ensure Thermal Stability and Uniformity during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Rats
por: Löke, Daan R., et al.
Publicado: (2020)

Validation of thermal dynamics during Hyperthermic IntraPEritoneal Chemotherapy simulations using a 3D-printed phantom
por: Löke, Daan R., et al.
Publicado: (2023)

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure
por: Chiancone, Francesco, et al.
Publicado: (2021)

Simulating drug penetration during hyperthermic intraperitoneal chemotherapy
por: Löke, Daan R., et al.
Publicado: (2021)

Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review
por: Helderman, Roxan F. C. P. A., et al.
Publicado: (2019)

Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain
por: Plata, Ana, et al.
Publicado: (2021)

Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
por: Molenaar, Remco J., et al.
Publicado: (2019)

The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines
por: Helderman, Roxan F.C.P.A., et al.
Publicado: (2020)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Elevated temperatures and longer durations improve the efficacy of oxaliplatin- and mitomycin C-based hyperthermic intraperitoneal chemotherapy in a confirmed rat model for peritoneal metastasis of colorectal cancer origin
por: Helderman, Roxan F. C. P. A., et al.
Publicado: (2023)

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Modulating the Heat Stress Response to Improve Hyperthermia-Based Anticancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2021)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Non-Invasive Imaging and Scoring of Peritoneal Metastases in Small Preclinical Animal Models Using Ultrasound: A Preliminary Trial
por: Helderman, Roxan F. C. P. A., et al.
Publicado: (2022)

HyCHEED System for Maintaining Stable Temperature Control during Preclinical Irreversible Electroporation Experiments at Clinically Relevant Temperature and Pulse Settings
por: Agnass, Pierre, et al.
Publicado: (2020)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2022)

Enhancement of Radiation Effectiveness in Cervical Cancer Cells by Combining Ionizing Radiation with Hyperthermia and Molecular Targeting Agents
por: IJff, Marloes, et al.
Publicado: (2018)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Sensitizing thermochemotherapy with a PARP1-inhibitor
por: Oei, Arlene L, et al.
Publicado: (2016)

Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all
por: Oei, Arlene L., et al.
Publicado: (2015)

Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette–Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2021)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
por: Hendricksen, Kees, et al.
Publicado: (2009)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
por: Ord, J J, et al.
Publicado: (2005)

PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation
por: IJff, Marloes, et al.
Publicado: (2021)

Radiosensitization by Hyperthermia: The Effects of Temperature, Sequence, and Time Interval in Cervical Cell Lines
por: Mei, Xionge, et al.
Publicado: (2020)

A versatile liquid-jet setup for the European XFEL
por: Schulz, J., et al.
Publicado: (2019)

An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
por: Jager, Auke, et al.
Publicado: (2022)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
por: Chiancone, Francesco, et al.
Publicado: (2020)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r1gssi149oc8ao2ek2glekkpk1